How antirheumatic drugs protect joints from damage in rheumatoid arthritis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Therapy in rheumatoid arthritis (RA) aims forthe containment of chronic inflammation as well asstructural protection of the affected joints. Both reduc-tion of inflammation and protection of joints fromdamage are considered central therapeutic goals in RA.Virtually all therapeutic agents used and developed forthe treatment of RA have been assessed for theirpotential to reach these 2 goals and, ideally, combine anantiinflammatory effect with a structure-sparing effect.Since the molecular mechanisms of synovitis, which areresponsible for the “inflammatory” signs of disease suchas swelling, pain, and stiffness, differ from the mecha-nisms leading to structural damage, antirheumatic drugsideally have to affect both mechanisms of disease.Inflammatory signs of RA are based on a chronicinflammatory process in the synovial membrane, whichis the result of an enhanced influx of immune cells aswell as synovial hyperplasia (1,2). Physiologically, only afew cells migrate into the normal synovium through thesynovial microvessels, and few cells escape this compart-ment to move toward regional lymph nodes through thelymphoendothelial microvessels. The enhanced influx ofimmune cells in inflammatory arthritis is regulated bychemokine and adhesion molecule expression in thesynovial tissue, which is induced by inflammatory cyto-kines such as tumor necrosis factor (TNF ) andinterleukin-1 (IL-1). Thus, joints are literally flooded byimmune cells, which accumulate in the synovial spaceand overflow the efflux mechanism through the lym-phatic vessels (3). This influx of immune cells, includingmacrophages, lymphocytes, dendritic cells, neutrophils,and mast cells, is accompanied by a response of theresident synovial fibroblasts (synovial hyperplasia),which express genes rendering them resistant to apopto-tic cell death as well as angiogenesis. Importantly, how-ever, this chronic inflammatory process in the synovialmembrane leads to profound damage of the surroundingtissue, particularly cartilage and bone. These destructivemechanisms are a consequence of an imbalance betweencatabolic and anabolic pathways induced by cytokinesand mediated by matrix-degrading enzymes (aggre-canases and matrix metalloproteinases [MMPs]) pro-duced by effector cells, including osteoclasts, fibroblasts,leukocytes, and chondrocytes.It is evident that inflammation is the driving forcein RA and gives rise to structural damage during thecourse of disease. The greater the inflammatory load towhich joints are exposed, the more likely it is forstructural damage to occur and the faster such damagewill progress. Risk predictors of structural damage inRA are thus the parameters that quantify inflammatoryload, such as the number of swollen joints or the level ofC-reactive protein (CRP) (4–6). Another key link be-tween inflammation and structural damage is time. Thelonger inflammation lasts, the more likely structuraldamage is to occur. Disease duration and parametersthat predict chronicity of arthritis, such as the presenceof anti–cyclic citrullinated peptide antibodies and/orrheumatoid factor, are associated with structural dam-age in RA (3–6). It is thus the chronicity of inflamma-tion that gives rise to structural damage of joints, andthisiswellreflected,forexample,bytheobservationthata transitory decrease in the acute component ofinflammation upon treatment with nonsteroidal anti-inflammatory drugs is not sufficient to achieve jointprotection. Accumulation of joint damage during thecourse of RA requires the presence of synovitis, which
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440
Maini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22033 · Cited by 790
Osteoclasts are essential for TNF-α-mediated joint destruction.
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215582 · Cited by 474
Self-citationLi, P., Schwarz, E. M., O'Keefe, R. J., Ma, L., Boyce, B. F., & Xing, L. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301233 · Cited by 220
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11150 · Cited by 150
Self-citationLee, C., Lee, E. Y., Chung, S. M., Mun, S. H., Yoo, B., & Moon, H. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20637 · Cited by 137
Cited by
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Self-citationPathogenetic insights from the treatment of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31472-1 · Cited by 1,345
Self-citationBone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.153 · Cited by 947
Self-citationThymoquinone and its therapeutic potentials
Darakhshan, S., Bidmeshki Pour, A., Hosseinzadeh Colagar, A., & Sisakhtnezhad, S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.011 · Cited by 507
Mechanisms and control of pathologic bone loss in periodontitis
Bartold, P. M., Cantley, M. D., & Haynes, D. R. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2010.00347.x · Cited by 254
Metadata
- Authors
- Schett, G., Stach, C., Zwerina, J., Voll, R., & Manger, B.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-09-29
- Volume
- 58
- Issue
- 10
- Pages
- 2936-2948
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2090355700
- Cited by
- 112
- References
- 8
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How antirheumatic drugs protect joints from damage in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.23951
- The paper
- Schett, G., Stach, C., Zwerina, J., Voll, R., & Manger, B. (2008). How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.23951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.